Vericel Corporation (VCEL) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Vericel Corporation (VCEL) right now is MACI franchise growth and label expansion: MACI is the core driver, growing revenue in the low-to-mid 20% range with a large addressable knee-cartilage-defect population and limited direct cell-therapy competition. Revenue (TTM) is ~$292M. If that keeps playing out, the setup is favourable; the risk to it is the stock trades at a rich multiple (high price-to-sales and a triple-digit trailing price-to-earnings), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors. No one can predict where VCEL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Vericel Corporation (VCEL) higher?
1. MACI franchise growth and label expansion
MACI is the core driver, growing revenue in the low-to-mid 20% range with a large addressable knee-cartilage-defect population and limited direct cell-therapy competition. Expanded indications (such as ankle) and a broadening surgeon base give a multi-year runway. Because MACI uses the patient's own cells, it faces no generic or biosimilar pathway.
2. Manufacturing capacity unlock
The FDA approved commercial MACI manufacturing at a new facility in early 2026, materially expanding production capacity. This removes a supply constraint on growth and supports higher gross margins over time as volume scales. It also enables a prospective UK launch pending marketing authorization.
3. Burn-care franchise and BARDA
Epicel and NexoBrid serve severe-burn patients with high unmet need. A ten-year BARDA agreement valued at up to roughly $197M underpins NexoBrid procurement, adding a government-backed, less cyclical revenue stream alongside strong recent Epicel growth.
4. Profitability and balance-sheet strength
Vericel is free-cash-flow positive with over $200M of cash and no debt, and it guides to roughly 27% adjusted EBITDA margins for 2026. That self-funding profile lets it invest in capacity and pipeline without dilution or leverage.
What could weigh on VCEL?
The stock trades at a rich multiple (high price-to-sales and a triple-digit trailing price-to-earnings), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors. Revenue is heavily concentrated in a single product, MACI, and depends on elective orthopedic procedure volumes that can soften in a weak economy. Reimbursement changes, surgeon-adoption pace, and the complexity of a personalized cell-manufacturing supply chain are ongoing execution risks. Larger orthopedics players such as Smith+Nephew, Stryker and Arthrex could pressure the broader cartilage-repair space over time. Burn-care revenue can be lumpy and partly dependent on government contracts.
Where VCEL trades today
A forecast starts from where the stock actually is. These are VCEL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for VCEL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a VCEL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the VCEL guide and whether VCEL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the VCEL outlook
The bottom line: what is driving Vericel Corporation (VCEL) is MACI franchise growth and label expansion, with revenue (ttm) at ~$292M. If that keeps playing out the setup is favourable; the risk is the stock trades at a rich multiple (high price-to-sales and a triple-digit trailing price-to-earnings), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors. No one can predict the price, so treat any VCEL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on VCEL
- VCEL stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is VCEL a buy? (the case for, the risks, and a framework to decide)
- Does VCEL pay a dividend?
Build a basket around VCEL with Walnut
Use Vericel Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Vericel Corporation (VCEL)?
+
No one can reliably predict where VCEL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Vericel Corporation higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive VCEL higher?
+
The main growth drivers are MACI franchise growth and label expansion; Manufacturing capacity unlock; Burn-care franchise and BARDA. Whether they play out is the real question, not a guaranteed path.
What are the risks to VCEL?
+
The stock trades at a rich multiple (high price-to-sales and a triple-digit trailing price-to-earnings), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors. Revenue is heavily concentrated in a single product, MACI, and depends on elective orthopedic procedure volumes that can soften in a weak economy. Reimbursement changes, surgeon-adoption pace, and the complexity of a personalized cell-manufacturing supply chain are ongoing execution risks. Larger orthopedics players such as Smith+Nephew, Stryker and Arthrex could pressure the broader cartilage-repair space over time. Burn-care revenue can be lumpy and partly dependent on government contracts.
Will VCEL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Vericel Corporation's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is VCEL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the VCEL "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Vericel growing?
+
Revenue has been growing in the 20-30% range, led by MACI. Q1 2026 revenue rose about 30% year over year, and management guides to roughly $326-336M in full-year 2026 revenue with about 27% adjusted EBITDA margins.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.